Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has issued an announcement.
Cambium Bio Limited has issued 4,363,637 new ordinary shares without a prospectus under provisions of the Corporations Act, and lodged the associated Appendix 2A with the ASX. The company confirmed it is up to date with its financial reporting and continuous disclosure obligations and stated there is no undisclosed price-sensitive information, signalling that the capital issuance is proceeding under normal regulatory compliance.
The cleansing notice provides assurance to investors that the newly issued shares can be traded on-market without additional disclosure requirements. This move modestly expands Cambium Bio’s share capital base while underscoring its adherence to corporate governance standards that support secondary market liquidity and investor confidence.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited is an Australian-listed biotechnology company trading on the ASX under the ticker CMB. The company operates in the life sciences sector, focusing on biomedical technologies and related innovations from its base in Bella Vista, New South Wales.
Average Trading Volume: 11,160
Technical Sentiment Signal: Sell
Current Market Cap: A$11.02M
See more data about CMB stock on TipRanks’ Stock Analysis page.